Does this news make the FTSE 100’s Royal Bank of Scotland a screaming ‘buy’?

This is what I’d do with the shares of Royal Bank of Scotland Group plc (LON: RBS) now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Last week, Royal Bank of Scotland Group (LSE: RBS) announced its chief executive Ross McEwan intends to retire. The firm also put out its first-quarter interim management statement. Should I buy some of the company’s shares on the news?

Plenty of change in the board room

Generally, I like change at the top in a company because new management can bring renewed ambition, drive and enthusiasm to the direction of an enterprise. And shareholders are certainly seeing change because the announcement comes hard on the heels of the appointment of new chief financial officer Katie Murray last December. RBS has lurched into a “worldwide” hunt for its next chief and McEwan will stay in post until the new executive is in place while working out his 12-month notice period.

But McEwan could be timing his departure well. In the recent management statement, the company said it expects ongoing Brexit uncertainty on the economy and associated delay in business borrowing decisions make income growth “more challenging” in the near term.

However, I’m uncertain about the bank’s prospects in the medium term, and in the longer-term too. The outfit is a highly cyclical operation – as are all the London-listed banks – and I reckon sustainable income growth is challenging at the best of times.

RBS has earned its low valuation

Erratic profits, cash flows, dividend payments and share prices are the normal way of things for the banks. When things are going well and profits have been riding high, we often see low-looking valuations. But there’s a good reason for that. I think the stock market is marking down the valuation in preparation for the next cyclical plunge, which could arrive at any time, or perhaps not for years. The uncertainty of it all is what keeps me away from bank shares such as RBS right now.

McEwan has been leading the company since October 2013, and this table shows the financial record over the period:

Year to December

2013

2014

2015

2016

2017

2018

Normalised earnings per share

(53.2)

20.5

15.2

(15.2)

19.9

25.5

Operating cash flow per share

(273.6)

(179.5)

7.97

(31.2)

324.6

(1.86)

Dividend per share

0

0

0

0

0

5.5p

Those erratic figures for cash flow and earnings look scary to me, especially those deep plunges into the negative. However, I think the dividend history tells the story of how hard the firm has struggled. The payment only reappeared in 2018, around a decade after the financial crisis.

Admittedly, City analysts predict further dividend increases ahead, but McEwan is going because he reportedly thinks the bank has turned around. That worries me because if the firm has returned to ‘normal’ it could be near to peak profits in the current macroeconomic cycle. And the thing about cycles is that troughs follow peaks and vice versa.

I don’t have the stomach to invest in RBS now despite its low-looking valuation. I reckon the valuation ‘anomaly’ could ‘correct’ by means of profits disappearing again down the line.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »